
Novo Nordisk has eliminated its U.S. cardiometabolic educator sales team, comprising several hundred staff, as an initial step in a broader restructuring plan to cut costs and enhance competitiveness against Eli Lilly. This move, following a significant loss in market capitalization and the announcement of 9,000 global job cuts, signals CEO Maziar Mike Doustdar's strategy to streamline operations and regain market dominance in the weight-loss drug sector.
Novo Nordisk is executing the initial phase of a significant corporate restructuring by eliminating its U.S. cardiometabolic educator team, a unit comprising several hundred employees. This action represents the first specific cut under new CEO Maziar Mike Doustdar's plan to reduce the global workforce by 9,000. The move is a direct response to intense competitive pressure from Eli Lilly, which has captured market dominance in the U.S. weight-loss drug sector and contributed to Novo Nordisk losing over $400 billion in market capitalization since the middle of last year. By disbanding a team focused on 'disease state education'—a function its primary rival Eli Lilly does not have—Novo is signaling a strategic shift to streamline operations and align its cost structure more closely with its competitor. While the broader restructuring has been met with initial investor approval, this specific layoff underscores the company's defensive posture as it attempts to regain profitability and market share.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment